PolyNovo Limited (ASX:PNV): Can Complex Wound Products Sustain Growth Beyond Burns?

Aditi Sarkar

11 November 2026 04:49 PM AEDT

PolyNovo Limited (ASX:PNV): Can Complex Wound Products Sustain Growth Beyond Burns?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY26 total Revenue reached AUD 150.0 million, a 16.1% increase on FY25.
Commercial sales grew 16.7% to AUD 138.4 million, led by the United States.
NovoSorb MTX sales rose 89.6% to AUD 12.6 million during FY26.
Expanded Manufacturing and regulatory work remain important to FY27 execution.

PolyNovo Limited (ASX:PNV) develops and markets medical devices based on its NovoSorb polymer platform for burns and complex wounds. Its products include NovoSorb BTM and NovoSorb MTX, sold through direct operations and distributors in international markets. The company’s FY26 results show revenue growth alongside an increasing contribution from applications beyond major burns, while manufacturing expansion and regulatory preparations provide the operational background for its next phase.

FY26 Commercial Sales and Geographic Mix

For the year ended 30 June 2026, PolyNovo Limited (ASX:PNV) reported total revenue of AUD 150.0 million, up 16.1% from AUD 129.2 million in FY25. Commercial product sales increased 16.7% to AUD 138.4 million, or 21.3% on a constant-currency basis. The distinction matters because exchange-rate movements affect reported Australian-dollar growth when overseas markets account for a substantial share of demand.

US commercial sales reached AUD 102.1 million, increasing 15.6%, while sales outside the United States rose 20.0% to AUD 36.3 million. This geographic spread provides several routes to expand product use, but the United States remains the largest contributor. Clinical uptake, market access and reimbursement conditions therefore have a material bearing on revenue performance.

NovoSorb MTX and Uses Beyond Major Burns

NovoSorb MTX generated AUD 12.6 million of sales in FY26, compared with AUD 6.7 million in FY25, an increase of 89.6%. NovoSorb BTM sales were AUD 125.8 million, meaning the older product retained the majority of the group’s commercial revenue. PolyNovo Limited (ASX:PNV) has highlighted rising activity in other complex wound indications, in addition to burns treatment.

The company has been building clinical evidence for applications including reconstructive procedures and other difficult wounds. A broader evidence base can support discussions with hospitals and clinicians, although published studies do not automatically result in regulatory clearance or reimbursement for every intended use. Commercial momentum still depends on clinician adoption and the Economics of individual treatment settings.

Profit, Cash Flow and Manufacturing

FY26 EBITDA was AUD 12.1 million, compared with AUD 11.2 million in FY25. Net profit after tax fell to AUD 7.3 million from AUD 13.2 million, partly reflecting differing tax outcomes between the periods. These measures should not be treated as interchangeable: operating Earnings improved modestly while statutory net profit declined.

The group reported Operating Cash Flow of AUD 23.1 million and free cash flow of AUD 9.4 million in FY26. Cash and cash equivalents totalled AUD 35.4 million at 30 June 2026. PolyNovo Limited (ASX:PNV) completed construction of its expanded manufacturing facility, with validation and transition activities forming part of the FY27 programme. Manufacturing capacity alone does not establish the timing of future sales.

Regulatory Priorities and Commercial Risks

The company has prioritised a US premarket approval submission for NovoSorb BTM in full-thickness burns, supported by its completed clinical study report. Its FY26 disclosures indicated an intention to submit the application before the end of calendar 2026. Submission and eventual approval are separate milestones, and approval timing is not guaranteed.

PolyNovo Limited (ASX:PNV) is also preparing an outpatient strategy and pursuing wider MTX adoption. US reimbursement changes, competition, clinical evidence and the launch of new products remain practical execution considerations. Higher sales volumes must translate into sustainable margins and cash generation if the expanded platform is to improve financial performance.

Key Insights

PolyNovo Limited (ASX:PNV) achieved FY26 commercial growth, especially in the United States and NovoSorb MTX. Its principal uncertainties relate to US reimbursement, regulatory progress, manufacturing scale-up and the conversion of wider clinical use into durable profitability.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.